Danske Bank A/S
20.7.2026 10:00:00 CEST | Globenewswire | Press release
Danske Bank share buy-back programme: transactions in week 29
Danske Bank share buy-back programme: transactions in week 29
| Company announcement no. 37 2026 | Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 33 44 00 00 20 July 2026 Page 1 of 2 |
Danske Bank share buy-back programme: transactions in week 29
On 5 February 2026, Danske Bank A/S announced a share buy-back programme for a total of DKK 4.5 billion, with a maximum of 45,000,000 shares, in the period from 9 February 2026 to 29 January 2027, at the latest, as described in company announcement no. 6 2026.
The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules").
The following transactions were made under the share buy-back programme in week 29:
| Number of shares | VWAP DKK | Gross value DKK | |
| Accumulated, last announcement | 5,893,956 | 326.0770 | 1,921,883,433 |
| 13 July 2026 | 343,948 | 366.9383 | 126,207,694 |
| 14 July 2026 | 290,652 | 367.9570 | 106,947,438 |
| 15 July 2026 | 14,717 | 371.9608 | 5,474,147 |
| 16 July 2026 | 14,707 | 370.1762 | 5,444,181 |
| 17 July 2026 | 14,924 | 364.5505 | 5,440,552 |
| Total accumulated over week 29 | 678,948 | 367.5009 | 249,514,012 |
| Total accumulated during the share buyback programme | 6,572,904 | 330.3559 | 2,171,397,445 |
With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 0.806% of Danske Bank A/S’ share capital.
Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
Danske Bank
Contact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70
| Nasdaq Copenhagen | Number of shares | VWAP DKK | Gross value DKK |
| 13 July 2026 | 228,423 | 366.8714 | 83,801,866 |
| 14 July 2026 | 176,169 | 367.8820 | 64,809,404 |
| 15 July 2026 | 9,352 | 372.1087 | 3,479,961 |
| 16 July 2026 | 8,972 | 370.1668 | 3,321,137 |
| 17 July 2026 | 9,067 | 364.2914 | 3,303,030 |
| Total accumulated over week 29 | 431,983 | 367.4112 | 158,715,397 |
| Total accumulated during the share buyback programme | 4,169,720 | 330.4202 | 1,377,759,519 |
| CBOE Europe | Number of shares | VWAP DKK | Gross value DKK |
| 13 July 2026 | 115,525 | 367.0707 | 42,405,843 |
| 14 July 2026 | 114,483 | 368.0724 | 42,138,033 |
| 15 July 2026 | 5,365 | 371.7030 | 1,994,187 |
| 16 July 2026 | 5,735 | 370.1908 | 2,123,044 |
| 17 July 2026 | 5,857 | 364.9518 | 2,137,523 |
| Total accumulated over week 29 | 246,965 | 367.6579 | 90,798,629 |
| Total accumulated during the share buyback programme | 2,403,184 | 330.2443 | 793,637,918 |
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Cosmos Health Inc.24.8.2026 21:40:00 CEST | Press release
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Kitron ASA24.8.2026 17:07:52 CEST | Press release
Kitron revises full-year 2026 outlook upwards
Zealand Pharma24.8.2026 17:05:00 CEST | Press release
Zealand Pharma – Notification of holding of treasury shares
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom